Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chromogranin A

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Chromogranin A. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-002275-40 Sponsor Protocol Number: 2006-002275-40 Start Date*: 2007-01-24
    Sponsor Name:Uppsala University Hospital, Dept. of Medical Sciences
    Full Title: Prospective study of patients treated with pegylated interferon-alpha 2b (PegIntron) for metastasizing ileal/coecal carcinoids
    Medical condition: Metastasizing ileal/coecal carcinoids (WHO ICD-10 code: C17.9)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-002338-31 Sponsor Protocol Number: 47 Start Date*: 2008-08-29
    Sponsor Name:Hannover Medical School
    Full Title: Prospektive randomisierte Phase II Studie zur Behandlung von Patienten mit fortgeschrittenem hormonrefraktären Prostatakarzinom mittels LHRH-Analoga und Somatostatin-Analoga unter Berücksichtigung ...
    Medical condition: Patients with hormone - independent non metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022975-67 Sponsor Protocol Number: 2010-022975-67 Start Date*: 2011-03-31
    Sponsor Name:AZIENDA U.L.S.S. N.8 DI ASOLO
    Full Title: 68Ga-DOTANOC as a PET tool to diagnose nueroendocrine tumors
    Medical condition: Study of tumor neuroendocrin origin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006731-45 Sponsor Protocol Number: PB-2006-01 Start Date*: 2007-04-26
    Sponsor Name:Køge Sygehus
    Full Title: PPI-Rebound-Trial
    Medical condition: This is a healthy volunteer trial designed to investigate if long-term treatment with nexium is the cause of a clinically significant acid rebound phenomenon. The intended indication for nexium is ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004373-40 Sponsor Protocol Number: AveNEC Start Date*: 2017-08-21
    Sponsor Name:University Medical Center of the Johannes Gutenberg-University Mainz
    Full Title: A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in patients with advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010) pr...
    Medical condition: advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001098-94 Sponsor Protocol Number: D12-01 Start Date*: 2014-04-18
    Sponsor Name:GERCOR
    Full Title: A randomized phase II double-blind trial of sunitinib versus placebo in combination with lanreotide in patients with progressive advanced/metastatic midgut carcinoid tumors
    Medical condition: Progressive advanced/metastatic midgut carcinoid tumors
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068118 Metastatic carcinoid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004363-74 Sponsor Protocol Number: A6181202 Start Date*: 2012-02-02
    Sponsor Name:Pfizer Inc.
    Full Title: A SINGLE ARM OPEN LABEL INTERNATIONAL MULTI CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT®) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL DIFFERENTIATED UNRE...
    Medical condition: PROGRESSIVE ADVANCED METASTATIC WELL DIFFERENTIATED UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) HU (Completed) ES (Completed) BE (Completed) PT (Completed) PL (Completed) SK (Completed) EE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002183-27 Sponsor Protocol Number: T-019 Start Date*: 2013-04-03
    Sponsor Name:Hammersmith Medicines Research
    Full Title: Can netazepide eradicate the inflammatory response of the gastric mucosa to H. pylori infection?
    Medical condition: Gastritis associated with H. pylori infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10051790 Helicobacter pylori gastritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-004735-39 Sponsor Protocol Number: M14NEC Start Date*: 2015-11-10
    Sponsor Name:NKI-AVL
    Full Title: Phase II Study of cisplatin and everolimus in patients with metastatic or unresectable neuroendocrine carcinomas (NEC) of extrapulmonary origin
    Medical condition: Patients with metastatic neuroendocrine carcinomas of extrapulmonary origin will be eligible
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004550-28 Sponsor Protocol Number: AIO-NET-0112 Start Date*: 2015-03-12
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: EVINEC: Safety and Tolerability of Everolimus as second-line treatment in poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumor...
    Medical condition: • Poorly differentiated neuroendocrine carcinoma, neuroendocrine carcinoma G3 (NEC G3 according to WHO 2010) with primary tumor outside lung • Well to moderately differentiated neuroendocrine carci...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002887-26 Sponsor Protocol Number: CRAD001T2302 Start Date*: 2012-04-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of ...
    Medical condition: Advanced neuroendocrine tumor (NET) of GI or lung origin
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Completed) CZ (Completed) HU (Completed) ES (Completed) GB (Completed) IT (Completed) NO (Completed) NL (Completed) GR (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-006819-75 Sponsor Protocol Number: CRAD001C2324 Start Date*: 2007-10-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine t...
    Medical condition: Pancreatic neuroendocrine tumors (also called pancreatic endocrine tumors or islet cell tumors (ICT))
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033630 Pancreatic islet cell neoplasm malignant NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Completed) DE (Completed) ES (Completed) FR (Completed) GR (Completed) BE (Completed) GB (Completed) SK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004904-35 Sponsor Protocol Number: Protocol2-55-52030-726 Start Date*: 2006-08-14
    Sponsor Name:IPSEN PHARMA S.A.S.
    Full Title: Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multicentre study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg ...
    Medical condition: Non functioning entero-pancreatic tumours
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) BE (Completed) DK (Completed) CZ (Completed) GR (Completed) SE (Completed) DE (Completed) AT (Completed) IT (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-006824-20 Sponsor Protocol Number: CSOM230BDE02 Start Date*: 2007-11-08
    Sponsor Name:Universitätsklinikum Essen - Zentrum für Innere Medizin - Klinik für Endokrinologie
    Full Title: Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Pheochromocytoma – proof of concept study
    Medical condition: Pheochromocytoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034876 Pheochromocytoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-002420-18 Sponsor Protocol Number: PTK787/ZK NET 2004 Start Date*: Information not available in EudraCT
    Sponsor Name:Prof. B. Wiedenmann, Klinik für Gastroenterologie, Charité, Campus Virchow
    Full Title: A prospective, non-randomized, non-controlled, open label, multicenter phase II Study: PTK 787/ ZK222584 in patients with advanced neuroendocrine tumors.
    Medical condition: This is a non-randomized, non-controlled, open label, multicenter phase II study to evaluate the efficacy and safety of PTK 787/ ZK 222584 in the treatment of patients with·progressive neuroendocri...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2013-002138-20 Sponsor Protocol Number: CURTAXEL Start Date*: 2013-10-09
    Sponsor Name:Centre Jean Perrin
    Full Title: Multicenter randomized phase II study, double-blind, comparing Taxotere plus curcumin versus Taxotere plus placebo combination in first-line treatment of prostate cancer metastatic castration resis...
    Medical condition: metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10066489 Progression of prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001207-68 Sponsor Protocol Number: KKSH140 Start Date*: 2018-11-20
    Sponsor Name:Martin-Luther-Universität Halle-Wittenberg
    Full Title: A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors
    Medical condition: Progressive well-differentiated metastatic pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    21.0 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019862-10 Sponsor Protocol Number: A-93-52030-738 Start Date*: 2010-12-06
    Sponsor Name:IPSEN
    Full Title: Randomised, phase III multicenter, open study of lanreotide in non metastatic castration-resistant prostate cancer patients presenting elevated Chromogranin A levels
    Medical condition: Patients with prostate cancer presenting Neuro-Endocrine (NE) differentiation developing non metatstatic castrate resistant disease and eligible to second line hormone treatment with non steroidal ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029104 SOC
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001550-29 Sponsor Protocol Number: AXI-IIG-02 Start Date*: 2011-08-11
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos
    Full Title: A Phase II randomized double-blind study of Santostatin LAR in combination with Axitinib versus Placebo in patients with progressive advanced well-differentiated neuroendocrine carcinomas of non-pa...
    Medical condition: Patients with progressive advanced well-differentiated neuroendocrine carcinomas of non-pancreatic origin (carcinoids)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013222-16 Sponsor Protocol Number: 8-55-52060-004 Start Date*: 2009-12-02
    Sponsor Name:Ipsen Pharma
    Full Title: Phase II, open, adaptive, dose escalating, multicentre titration study to assess the efficacy and safety of repeated subcutaneous administration of different doses of BIM 23A760 in patients with ca...
    Medical condition: carcinoid syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.0 10007270 Carcinoid syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) NL (Prematurely Ended) LV (Prematurely Ended) CZ (Prematurely Ended) FI (Prematurely Ended) IE (Completed) ES (Prematurely Ended) BE (Completed) AT (Prematurely Ended) FR (Completed) DE (Prematurely Ended) IT (Prematurely Ended) SK (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 17:49:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA